Market Overview

Fossil Group, Myriad Genetics Among The Earnings Reports To Keep An Eye On Tuesday

Related FOSL
10 Worst Stocks Of 2017
44 Biggest Movers From Friday
Related CREE
Benzinga's Top Upgrades, Downgrades For December 19, 2017
30 Stocks Moving In Monday's Pre-Market Session

Fossil Group Inc (NASDAQ: FOSL), Cree, Inc. (NASDAQ: CREE), Symantec Corporation (NASDAQ: SYMC) and Myriad Genetics, Inc. (NASDAQ: MYGN) are scheduled to announce their quarterly financial results on Tuesday evening, after the market closes. So, let’s take a look at what the Street, the crowd and management are expecting for the calls.

Fossil Group

Although Fossil’s management guided earnings in the $1.18 per share - $1.29 per share range, and revenues of $804.77 million to $820.25 million, substantially up year-over-year, the market is expecting something quite different.

For the second quarter of the year, the Street is modeling consensus earnings of $0.84 per share on revenue of $751.57 million, while the crowd is projecting earnings of $0.92 per share on revenue of $762.02 million (Estimize).

These figures imply a decline of at least 6 percent from the earnings of $0.98 per share (on revenue of $774 million) reported in the second quarter of 2014 and almost flat earnings when compared to last quarter’s $0.91 per share – on sales of $725 million.

However, it should be noted in the chart above that Fossil has a history of surpassing both estimates and guidance.


Similar is the case for Cree. Management has guided earnings of $0.26 per share on revenue of $430 million, down from EPS of $0.42 on sales of $436.3 million reported a year ago, but up from last quarter’s EPS of $0.22 and revenue of $409.52 million.

Nonetheless, the crowd seems more bearish and anticipates earnings of $0.00 per share on revenue of $387.08 million.

The most pessimistic is the Street, which expects a consensus net loss of ($0.08) per share and revenue of $384.9 million.

Symantec & Myriad Genetics

A year ago, Symantec reported first quarter (fiscal 2015) earnings of $0.45 per share on revenue of $1.735 billion. For the current quarter (Q1 fiscal 2016), management, the Street and the crowd are expecting earnings of $0.43 per share on revenue in the range of $1.52 billion to $1.525 billion.

Finally, there’s Myriad Genetics, which is also expected to post a small year-over-year decline in earnings, from $0.48 per share reported a year ago to $0.41 per share this quarter.

Posted-In: EstimizeEarnings Previews Movers Trading Ideas


Related Articles (CREE + FOSL)

View Comments and Join the Discussion!